rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken
Aandeel

Fagron BE0003874915

Laatste koers (eur)

19,440

  • Verschil

    +0,480 +2,53%

  • Volume

    49.076 Gem. (3M) 64,2K

  • Bied

    19,420  

  • Laat

    19,460  
+ In watchlist

Fagron November 2016

247 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste | Omlaag ↓
  2. löngterm 1 november 2016 09:41

    • löngterm

      Lid sinds: 16 jan 2016

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 247

      Gegeven: 208

    •    Aantal posts: 1.948

    Beginnen de maand op 9 en eindigen op 10,50 naar mijn verwachting. Sentiment slaat wel om verkiezingen uit de weg en shorters hebben hun buit ook wel weer binnen.
  6. Peter Markus 1 november 2016 13:15

    • Peter Markus

      Lid sinds: 08 sep 2015

      Laatste bezoek: 01 nov 2022

    • Aanbevelingen

      Ontvangen: 968

      Gegeven: 389

    •    Aantal posts: 4.651

    Aandeeltje,
    Mooi instapmoment.
    Denk dat dit aandeel niet veel verder zal dalen.
    Volgens Tostram beperkt neerwaarts risico en hoog stijgingspotentieel.
    Zelf heb ik gekocht op 10,015 en 9.54.
    Groet PM
  8. Azoia 1 november 2016 15:57

    • Azoia

      Lid sinds: 12 sep 2016

      Laatste bezoek: 12 jul 2024

    • Aanbevelingen

      Ontvangen: 16

      Gegeven: 61

    •    Aantal posts: 201

    Ik verwacht dat er toch eerst eens nieuws moet komen wat er in USA is besproken voordat we weer wat rust in het aandeel krijgen. Tot nu toe dalen we alleen maar. Voor je het weet staan we bij de steun als we zo doorgaan.

  9. [verwijderd] 1 november 2016 18:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De Belgische FSMA heeft voor de 2e dag op rij de shortposities niet bijgewerkt.

    De laatste stand is van afgelopen donderdag met 1,79% oftewel ca. 1,3 miljoen aandelen, verdeeld over 3 partijen. (0,5% - 0,6% - 0,69%).
  10. [verwijderd] 1 november 2016 19:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Er hangen claims boven dit aandeel uit USA
    de koers gaat terg naar de 4.50
    op basis van lucht en oppompen omhoog
    kijk naar Ordina zelfde verhaal boemm 16% eraf
    dit aandeel gaat de zelfde kant op
    Tostrams geeft verkoopsignaal
  12. Azoia 1 november 2016 20:39

    • Azoia

      Lid sinds: 12 sep 2016

      Laatste bezoek: 12 jul 2024

    • Aanbevelingen

      Ontvangen: 16

      Gegeven: 61

    •    Aantal posts: 201

    quote:

    moneymaker_BX schreef op 1 november 2016 19:22:

    Er hangen claims boven dit aandeel uit USA
    de koers gaat terg naar de 4.50
    op basis van lucht en oppompen omhoog
    kijk naar Ordina zelfde verhaal boemm 16% eraf
    dit aandeel gaat de zelfde kant op
    Tostrams geeft verkoopsignaal
    Is het mogelijk er wen bron bij te vermelden?

    Ik kan allen dit vinden
    www.tostrams.nl/artikel-detail.aspx?I...

    Fagron valt door de steun 8,99 aan de onderkant van het zijwaarts gerichte koerspatroon.
    Fagron is door verkopers door de voorgaande bodem gedrukt. Hierdoor is een technische verzwakking opgetreden. Een dalende trend wordt gestart richting steun 8,15 (gevormd op 12 september). Enkel boven weerstand 10,59 (gevormd op 11 oktober) klaart het beeld op
  13. löngterm 1 november 2016 21:53

    • löngterm

      Lid sinds: 16 jan 2016

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 247

      Gegeven: 208

    •    Aantal posts: 1.948

    quote:

    moneymaker_BX schreef op 1 november 2016 19:22:

    Er hangen claims boven dit aandeel uit USA
    de koers gaat terg naar de 4.50
    op basis van lucht en oppompen omhoog
    kijk naar Ordina zelfde verhaal boemm 16% eraf
    dit aandeel gaat de zelfde kant op
    Tostrams geeft verkoopsignaal
    Hebben we hem ook weer zeg...
    eurotje er af nadat we zo'n 6 omhoog zijn gegaan en meneer begint meteen weer heerlijk te bashen.

    Koersen gaan nooit maar 1 kant op zo ook met Fagron een dipje is niets mis mee.
  14. [verwijderd] 2 november 2016 10:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Fagron stuitert altijd flink, maar er zit al een tijd een mooie lijn in. Dit is tijdelijk.

    Je zou overigens eens op het Tomtom forum moeten roepen dat de koers naar 3 euro gaat i.v.m. claims en 'lucht'...
  15. Peter Markus 2 november 2016 10:47

    • Peter Markus

      Lid sinds: 08 sep 2015

      Laatste bezoek: 01 nov 2022

    • Aanbevelingen

      Ontvangen: 968

      Gegeven: 389

    •    Aantal posts: 4.651

    Omaneus,
    Jouw 8 euro is in zicht.
    Zelf zit ik er vol in met een gemiddelde aankoopprijs van 9.81.
    Stijgingen en dalingen horen er gewoon bij.
    Heb er nog steeds alle vertrouwen in dat we eind van het jaar ergens tussen de 11.50 en 12 euro staan.
    Groet PM
  16. Azoia 2 november 2016 10:53

    • Azoia

      Lid sinds: 12 sep 2016

      Laatste bezoek: 12 jul 2024

    • Aanbevelingen

      Ontvangen: 16

      Gegeven: 61

    •    Aantal posts: 201

    Pfizer : Cuts Outlook, Ends Development of Cholesterol Drug
    0
    11/01/2016 | 12:56pm CET
    By Austen Hufford and George Stahl
    Pfizer Inc. on Tuesday lowered its earnings outlook for the year and said it was ending the development of a drug in the massive cholesterol-treatment sector.

    Shares of the company fell 2.2% premarket.

    Pfizer said it ended development of its cholesterol treatment bococizumab because it was losing efficacy over time in lowering so-called bad cholesterol. Bococizumab is part of a class of drugs, known as PCSK9 inhibitors, which aims to reduce levels of low-density lipoprotein cholesterol beyond what can be achieved by an older class of drugs known as statins. Lower levels of LDL is associated with reduced risk of heart attacks and strokes, but it hasn't been proven in trials that this type of drug actually has reduced cardiovascular risk.

    The company plans to record a charge of 4 cents a share in the fourth quarter because of costs from the program's discontinuation.

    For the full year, Pfizer said it now expects earnings per share of $2.38 to $2.43, reducing the high-end of the range by 5 cents. It also now expects revenue of between $52 billion to $53 billion, increasing the low end of the revenue forecast by $1 billion.

    In September, Pfizer said it had decided not to split into two companies after long considering the move. Pfizer spent at least $600 million preparing for a potential split before deciding not to, saying a supposed "valuation gap" between the company's market value and the value of its individual units has closed over time.

    In the latest quarter, Pfizer reported a profit of $1.32 billion, or 21 cents a share, down from $2.13 billion, or 34 cents a share a year prior. Excluding certain items, adjusted earnings were 61 cents a share, up from 60 cents.

    Revenue rose 7.9% to $13.05 billion.

    Analysts polled by Thomson Reuters had forecast adjusted earnings of 62 cents a share on revenue of $13.05 billion.

    Write to Austen Hufford at austen.hufford@wsj.com and George Stahl at george.stahl@wsj.com
  17. Azoia 2 november 2016 10:54

    • Azoia

      Lid sinds: 12 sep 2016

      Laatste bezoek: 12 jul 2024

    • Aanbevelingen

      Ontvangen: 16

      Gegeven: 61

    •    Aantal posts: 201

    Shire : Cuts Guidance After Posting Third-Quarter Loss
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/01/2016 | 02:03pm CET
    By Denise Roland
    Shire PLC cut its full-year guidance and reported a net loss in the three months to Sept. 30, both because of heavy spending on the integration of its $32 billion acquisition of Baxalta Inc.

    Dublin-based Shire said it would post a diluted loss per American Depository Share of between 70 cents and $1.10 in 2016, having previously said it would post between zero earnings per ADS and a 40 cent loss. The company reported a net loss of $387 million for the three months to Sept. 30. Meanwhile, revenue more than doubled to $3.5 billion, from $1.7 billion a year earlier.

    Analysts expected net profit of $903 million and revenue of $3.6 billion. Non-GAAP operating income, a measure that strips out certain one-time gains and losses, as well as tax and interest, increased 73% to $1.3 billion.

    Write to Denise Roland at Denise.Roland@wsj.com
  18. Azoia 2 november 2016 10:55

    • Azoia

      Lid sinds: 12 sep 2016

      Laatste bezoek: 12 jul 2024

    • Aanbevelingen

      Ontvangen: 16

      Gegeven: 61

    •    Aantal posts: 201

    Valeant, Saddled With Debt, in Talks to Sell Big Drug Line
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/01/2016 | 09:05pm CET
    Valeant Pharmaceuticals International Inc. is in advanced talks to sell a big stomach-drug business to Japan's Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its hefty debt load.

    The companies could reach a deal for Salix Pharmaceuticals Ltd., which Valeant bought just a year-and-a-half ago for roughly $11 billion, in the coming weeks, people familiar with the matter said. The purchase price would include about $8.5 billion in cash and future royalty payments to Valeant, the people said.

    There is no guarantee the companies will reach a deal and, indeed, there is another unnamed potential bidder in the mix, the people said.

    Valeant confirmed the discussions late Tuesday, saying, "We are currently in discussions with third parties for various divestitures including but not limited to Salix. The discussions may or may not lead to a definitive agreement."

    Valeant shares jumped after The Wall Street Journal reported on the potential deal, rising 34% to close at $23.86.

    Should Valeant strike a deal, it would allow the company to largely pay back its bank lenders, removing a big area of concern for investors ever since the drugmaker became embroiled in an accounting scandal last year. Valeant has told investors it would work to reduce its debt load, but the company was expected to do so through a series of smaller steps.

    It would also likely allow Valeant's new chief executive, Joseph Papa, to focus on rebuilding Valeant's core franchises in skin and eye drugs, which have been struggling.

    If it sells Salix, Valeant's top-selling products would be an off-patent antidepressant named Wellbutrin and Bausch & Lomb's SofLens daily disposable contact lenses. The company would be expected to double down on its skin and eye drugs, such as some acne treatments and over-the-counter vitamins taken for eye health. Valeant also has high hopes for a psoriasis treatment, brodalumab, that is up for regulatory approval.

    Salix makes treatments for stomach disorders like traveler's diarrhea and irritable bowel syndrome, or IBS.

    For Takeda, the purchase would come after it lost out on earlier attempts to buy Salix and deliver big-selling gastrointestinal drugs it has been seeking to bolster its lineup of stomach remedies.

    At the time of Valeant's Salix deal, the Canadian drug company was riding high on a strategy of acquiring companies and consolidating their research-and-development budgets.

    But then Valeant's business tactics and accounting came under intense scrutiny, leading to government investigations and the departure of its CEO, Michael Pearson, and other executives.

    Valeant's highflying stock plunged on fears it wouldn't be able to keep up its prior pace of acquisition-led growth and that its $30 billion of debt was too much. Investors have been particularly focused on the roughly $12 billion Valeant owes banks, given that the vast majority of its $19 billion in public bonds don't start coming due before 2020. Valeant took on roughly half its current debt load to pay for Salix after it won a heated bidding war for the company.

    Valeant-with a market value of about $8.3 billion at Tuesday's close, after its stock had dropped more than 90% from its highs in 2015-has been working with a number of banks to explore sales of various assets, and these efforts are also progressing, the people said. Valeant preferred to sell other parts of its business, but Salix was viewed as the most attractive asset for rivals, they said.

    Selling Salix for less than it paid in April 2015 could hand Valeant a loss it could use to offset gains from other asset sales.

    Takeda swooped in with an offer to start the talks. Takeda, Japan's largest drugmaker by revenue, vied for Salix in the previous auction, and combined on an abortive offer for all of Valeant with private-equity TPG, The Wall Street Journal r eported earlier this year.

    Salix would give Takeda a drug for IBS called Xifaxan that Valeant had predicted could have $1 billion in sales this year. Sales haven't done as well as some analysts expected, however. Many Salix sales representatives left the company, and Xifaxan has faced fierce competition from a competing drug, Viberzi, from Allergan PLC. Meanwhile, Teva Pharmaceutical Industries Ltd. also is working on a generic version of Xifaxan.

    Takeda is likely betting that its sales force, which already sells products like a fast-growing ulcerative-colitis drug called Entyvio, could help increase sales of Xifaxan and other Salix products.

    Like other Japanese drug companies, Takeda is seeking growth in the U.S. and other lucrative markets to offset pressures in its home country. The Japanese company has singled out stomach treatments as a priority. In March, its U.S. unit said it was reorganizing to focus on gastrointestinal disorders, along with a few other conditions.

    Dana Mattioli

    Write to David Benoit at david.benoit@wsj.com and Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com
  19. Azoia 2 november 2016 10:57

    • Azoia

      Lid sinds: 12 sep 2016

      Laatste bezoek: 12 jul 2024

    • Aanbevelingen

      Ontvangen: 16

      Gegeven: 61

    •    Aantal posts: 201

    Pharmaceutical : Japan's Takeda shares halted on news of interest in Valeant assets
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/02/2016 | 06:39am CET
    Trading in shares of Japan's Takeda Pharmaceutical Co (>> Takeda Pharmaceutical Co Ltd) was suspended in Tokyo on Wednesday after news the company was interested in buying Canadian drugmaker Valeant Pharmaceuticals International Inc's (>> Valeant Pharmaceuticals Intl Inc) stomach-drug business.
    Trading in shares of Japan's Takeda Pharmaceutical Co (>> Takeda Pharmaceutical Co Ltd) was suspended in Tokyo on Wednesday after news the company was interested in buying Canadian drugmaker Valeant Pharmaceuticals International Inc's (>> Valeant Pharmaceuticals Intl Inc) stomach-drug business.

    People familiar with the matter told Reuters the deal for the sale of the Salix business could raise as much as $10 billion for Valeant.

    A Takeda spokesman said the company had no immediate comment but would release a comment through the stock exchange shortly.

    (Reporting by Chang-Ran Kim; Editing by Richard Pullin)

    Stocks treated in this article : Valeant Pharmaceuticals Intl Inc, Takeda Pharmaceutical Co Ltd
  20. Azoia 2 november 2016 10:58

    • Azoia

      Lid sinds: 12 sep 2016

      Laatste bezoek: 12 jul 2024

    • Aanbevelingen

      Ontvangen: 16

      Gegeven: 61

    •    Aantal posts: 201

    Valeant Nears $10 Billion Salix Sale -- WSJ
    share with twitter share with LinkedIn share with facebook share via e-mail
    0
    11/02/2016 | 07:49am CET
    By David Benoit and Jonathan D. Rockoff
    Valeant Pharmaceuticals International Inc. is in advanced talks to sell a big stomach-drug business to Japan's Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its hefty debt load.

    The companies could reach a deal for Salix Pharmaceuticals Ltd., which Valeant bought just a year-and-a-half ago for roughly $11 billion, in the coming weeks, people familiar with the matter said. The purchase price would include about $8.5 billion in cash and future royalty payments to Valeant, the people said.

    There is no guarantee the companies will reach a deal and, indeed, there is another unnamed potential bidder in the mix, the people said.

    Valeant confirmed the discussions late Tuesday, saying, "We are currently in discussions with third parties for various divestitures including but not limited to Salix. The discussions may or may not lead to a definitive agreement."

    Valeant shares jumped after The Wall Street Journal reported on the potential deal, rising 34% to close at $23.86.

    On Wednesday, Takeda said it was in discussions with many parties about potential deals to accelerate growth, but declined to comment directly on the Journal report.

    Should Valeant strike a deal, it would allow the company to largely pay back its bank lenders, removing a big area of concern for investors ever since the drugmaker became embroiled in an accounting scandal last year. Valeant has told investors it would work to reduce its debt load, but the company was expected to do so through a series of smaller steps.

    It would also likely allow Valeant's new chief executive, Joseph Papa, to focus on rebuilding Valeant's core franchises in skin and eye drugs, which have been struggling.

    If it sells Salix, Valeant's top-selling products would be an off-patent antidepressant named Wellbutrin and Bausch & Lomb's SofLens daily disposable contact lenses. The company would be expected to double down on its skin and eye drugs, such as some acne treatments and over-the-counter vitamins taken for eye health. Valeant also has high hopes for a psoriasis treatment, brodalumab, that is up for regulatory approval.

    Salix makes treatments for stomach disorders like traveler's diarrhea and irritable bowel syndrome, or IBS.

    For Takeda, the purchase would come after it lost out on earlier attempts to buy Salix and deliver big-selling gastrointestinal drugs it has been seeking to bolster its lineup of stomach remedies.

    At the time of Valeant's Salix deal, the Canadian drug company was riding high on a strategy of acquiring companies and consolidating their research-and-development budgets.

    But then Valeant's business tactics and accounting came under intense scrutiny, leading to government investigations and the departure of its CEO, Michael Pearson, and other executives.

    Valeant's highflying stock plunged on fears it wouldn't be able to keep up its prior pace of acquisition-led growth and that its $30 billion of debt was too much. Investors have been particularly focused on the roughly $12 billion Valeant owes banks, given that the vast majority of its $19 billion in public bonds don't start coming due before 2020. Valeant took on roughly half its current debt load to pay for Salix after it won a heated bidding war for the company.

    Valeant -- with a market value of about $8.3 billion at Tuesday's close, after its stock had dropped more than 90% from its highs in 2015 -- has been working with a number of banks to explore sales of various assets, and these efforts are also progressing, the people said. Valeant preferred to sell other parts of its business, but Salix was viewed as the most attractive asset for rivals, they said.

    Selling Salix for less than it paid in April 2015 could hand Valeant a loss it could use to offset gains from other asset sales.

    Takeda swooped in with an offer to start the talks. Takeda, Japan's largest drugmaker by revenue, vied for Salix in the previous auction, and combined on an abortive offer for all of Valeant with private-equity TPG, The Wall Street Journal r eported earlier this year.

    Salix would give Takeda a drug for IBS called Xifaxan that Valeant had predicted could have $1 billion in sales this year. Sales haven't done as well as some analysts expected, however. Many Salix sales representatives left the company, and Xifaxan has faced fierce competition from a competing drug, Viberzi, from Allergan PLC. Meanwhile, Teva Pharmaceutical Industries Ltd. also is working on a generic version of Xifaxan.

    Takeda is likely betting that its sales force, which already sells products like a fast-growing ulcerative-colitis drug called Entyvio, could help increase sales of Xifaxan and other Salix products.

    Like other Japanese drug companies, Takeda is seeking growth in the U.S. and other lucrative markets to offset pressures in its home country. The Japanese company has singled out stomach treatments as a priority. In March, its U.S. unit said it was reorganizing to focus on gastrointestinal disorders, along with a few other conditions.

    --Dana Mattioli contributed to this article.

    Write to David Benoit at david.benoit@wsj.com and Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com
  21. Peter Markus 2 november 2016 10:58

    • Peter Markus

      Lid sinds: 08 sep 2015

      Laatste bezoek: 01 nov 2022

    • Aanbevelingen

      Ontvangen: 968

      Gegeven: 389

    •    Aantal posts: 4.651

    Ben overigens nieuwsschierig waar het dieptepunt ligt.
    In eerste instantie dacht ik zo rond de 9 euro.
    Nu we daar doorheen zijn gezakt houd ik er zelfs rekening mee dat dat ook de oude bodem van rond de 8 kan zijn.
    Wel valt het me op dat de koopdruk iets aan het toenemen is, waardoor ik de verwachting heb dat we tegen een nieuwe bodem aan het aanhikken zijn.
    Maar tja de beurs doet toch wat ie wilt en maar rustig afwachten dus.
    Groet PM
247 Posts
Pagina: 1 2 3 4 5 6 ... 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in
Fagron

Van de redactie

  1. Met deze ETF kleurt uw portefeuille groen als de S&P 500 daalt
  2. 7 koopwaardige aandelen voor de lange termijn
  3. Dit aandeel is toegevoegd aan favorietenlijstje beleggers
  4. TA-column Nico Bakker: koopkansen bij Nvidia?
  5. Twee groeiaandelen met verdubbelpotentieel in vijf jaar
  6. Uit Big Tech en in opkomende markten? Kijk naar deze beleggingsfondsen
Meer artikelen